Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.
Elia BalestraEgidio BarbiViola CeconiVittorio Di MasoEster ConversanoMarco PennesiPublished in: Pediatric nephrology (Berlin, Germany) (2023)
In this patient affected by C3G, pioglitazone proved effective in reducing proteinuria levels.